ReP USP - Resultado da busca

Artigo de periodico
Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum (2022)
Monteiro, Lis Marie ; Löbenberg, Raimar ; Barbosa, Eduardo José ; Araujo, Gabriel Lima Barros de ; Sato, Paula Keiko ; Kanashiro, Edite Hatsumi Yamashiro ; Eliodoro, Raissa Heloisa de Araujo; Rocha, Mussya; Freitas, Vera Lucia Teixeira de ; Fotaki, Nikoletta; Bou-Chacra, Nadia Araci
Fonte: European Journal of Pharmaceutical Sciences. Unidades: FCF, IMT, FM
Assuntos: LIPÍDEOS, LEISHMANIOSE VISCERAL, DOENÇAS NEGLIGENCIADAS, NANOTECNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MONTEIRO, Lis Marie et al. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, v. 169, p. 1-11 art. 106097, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2021.106097. Acesso em: 01 set. 2024.
APA
Monteiro, L. M., Löbenberg, R., Barbosa, E. J., Araujo, G. L. B. de, Sato, P. K., Kanashiro, E. H. Y., et al. (2022). Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, 169, 1-11 art. 106097. doi:10.1016/j.ejps.2021.106097
NLM
Monteiro LM, Löbenberg R, Barbosa EJ, Araujo GLB de, Sato PK, Kanashiro EHY, Eliodoro RH de A, Rocha M, Freitas VLT de, Fotaki N, Bou-Chacra NA. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 169 1-11 art. 106097.[citado 2024 set. 01 ] Available from: https://doi.org/10.1016/j.ejps.2021.106097
Vancouver
Monteiro LM, Löbenberg R, Barbosa EJ, Araujo GLB de, Sato PK, Kanashiro EHY, Eliodoro RH de A, Rocha M, Freitas VLT de, Fotaki N, Bou-Chacra NA. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 169 1-11 art. 106097.[citado 2024 set. 01 ] Available from: https://doi.org/10.1016/j.ejps.2021.106097
Artigo de periodico
A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis (2020)
Souza, Aline de ; Yukuyama, Megumi Nishitani ; Barbosa, Eduardo José ; Monteiro, Lis Marie ; Faloppa, Ana Cristina Breithaupt; Calixto, Leandro Augusto; Araujo, Gabriel Lima Barros de ; Fotaki, Nikoletta; Löbenberg, Raimar ; Bou-Chacra, Nadia Araci
Fonte: Colloids and Surfaces B: Biointerfaces. Unidade: FCF
Assuntos: NANOPARTÍCULAS, LIPÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Aline de et al. A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids and Surfaces B: Biointerfaces, v. 193, p. 1-8 art. 111097, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.colsurfb.2020.111097. Acesso em: 01 set. 2024.
APA
Souza, A. de, Yukuyama, M. N., Barbosa, E. J., Monteiro, L. M., Faloppa, A. C. B., Calixto, L. A., et al. (2020). A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids and Surfaces B: Biointerfaces, 193, 1-8 art. 111097. doi:10.1016/j.colsurfb.2020.111097
NLM
Souza A de, Yukuyama MN, Barbosa EJ, Monteiro LM, Faloppa ACB, Calixto LA, Araujo GLB de, Fotaki N, Löbenberg R, Bou-Chacra NA. A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis [Internet]. Colloids and Surfaces B: Biointerfaces. 2020 ; 193 1-8 art. 111097.[citado 2024 set. 01 ] Available from: https://doi.org/10.1016/j.colsurfb.2020.111097
Vancouver
Souza A de, Yukuyama MN, Barbosa EJ, Monteiro LM, Faloppa ACB, Calixto LA, Araujo GLB de, Fotaki N, Löbenberg R, Bou-Chacra NA. A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis [Internet]. Colloids and Surfaces B: Biointerfaces. 2020 ; 193 1-8 art. 111097.[citado 2024 set. 01 ] Available from: https://doi.org/10.1016/j.colsurfb.2020.111097
Artigo de periodico
Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment (2019)
Monteiro, Lis Marie ; Löbenberg, Raimar ; Fotaki, Nikoletta; Araujo, Gabriel Lima Barros de ; Cotrim, Paulo César ; Bou-Chacra, Nadia Araci
Fonte: Journal of Global Antimicrobial Resistance. Unidades: FCF, FM
Assuntos: QUITOSANA, LEISHMANIA, NANOTECNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MONTEIRO, Lis Marie et al. Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment. Journal of Global Antimicrobial Resistance, v. 18, p. 279-283, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jgar.2019.06.006. Acesso em: 01 set. 2024.
APA
Monteiro, L. M., Löbenberg, R., Fotaki, N., Araujo, G. L. B. de, Cotrim, P. C., & Bou-Chacra, N. A. (2019). Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment. Journal of Global Antimicrobial Resistance, 18, 279-283. doi:10.1016/j.jgar.2019.06.006
NLM
Monteiro LM, Löbenberg R, Fotaki N, Araujo GLB de, Cotrim PC, Bou-Chacra NA. Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment [Internet]. Journal of Global Antimicrobial Resistance. 2019 ; 18 279-283.[citado 2024 set. 01 ] Available from: https://doi.org/10.1016/j.jgar.2019.06.006
Vancouver
Monteiro LM, Löbenberg R, Fotaki N, Araujo GLB de, Cotrim PC, Bou-Chacra NA. Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment [Internet]. Journal of Global Antimicrobial Resistance. 2019 ; 18 279-283.[citado 2024 set. 01 ] Available from: https://doi.org/10.1016/j.jgar.2019.06.006
Artigo de periodico
Highly water-soluble orotic acid nanocrystals produced by high-energy milling (2019)
Compri, Jéssica de Cássia Zaghi; Felli, Veni Maria Andres; Lourenço, Felipe Rebello ; Takatsuka, Takayuki; Fotaki, Nikoletta; Löbenberg, Raimar; Bou-Chacra, Nadia Araci ; Araujo, Gabriel Lima Barros de
Fonte: Journal of Pharmaceutical Sciences. Unidade: FCF
Assuntos: COMPOSTOS HETEROCÍCLICOS, SOLUBILIDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COMPRI, Jéssica de Cássia Zaghi et al. Highly water-soluble orotic acid nanocrystals produced by high-energy milling. Journal of Pharmaceutical Sciences, v. 108, n. 5, p. 1848-1856, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.xphs.2018.12.015. Acesso em: 01 set. 2024.
APA
Compri, J. de C. Z., Felli, V. M. A., Lourenço, F. R., Takatsuka, T., Fotaki, N., Löbenberg, R., et al. (2019). Highly water-soluble orotic acid nanocrystals produced by high-energy milling. Journal of Pharmaceutical Sciences, 108( 5), 1848-1856. doi:10.1016/j.xphs.2018.12.015
NLM
Compri J de CZ, Felli VMA, Lourenço FR, Takatsuka T, Fotaki N, Löbenberg R, Bou-Chacra NA, Araujo GLB de. Highly water-soluble orotic acid nanocrystals produced by high-energy milling [Internet]. Journal of Pharmaceutical Sciences. 2019 ; 108( 5): 1848-1856.[citado 2024 set. 01 ] Available from: https://doi.org/10.1016/j.xphs.2018.12.015
Vancouver
Compri J de CZ, Felli VMA, Lourenço FR, Takatsuka T, Fotaki N, Löbenberg R, Bou-Chacra NA, Araujo GLB de. Highly water-soluble orotic acid nanocrystals produced by high-energy milling [Internet]. Journal of Pharmaceutical Sciences. 2019 ; 108( 5): 1848-1856.[citado 2024 set. 01 ] Available from: https://doi.org/10.1016/j.xphs.2018.12.015

Unidades USP

ReP

Filtros

Autores

Autores USP

Assuntos

Afiliação dos autores externos não normalizada